🇺🇸 FDA

Drug profile · INN

lenalidomide

LENALIDOMIDE CELGENE EUROPE

approved L04AX07
US status
approved
Patents linked
4
News articles
0

Quick answer

lenalidomide (LENALIDOMIDE CELGENE EUROPE) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN lenalidomide
Brand LENALIDOMIDE CELGENE EUROPE
Route ORAL
Formulation CAPSULE
ATC code L04AX07
Originator Amneal Pharma Europe Ltd

Related patents

Search patents →

  1. US 11253591

    Combination of lenalidomide and polypeptide construct, and uses thereof

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10342869

    Compositions comprising anti-CD38 antibodies and lenalidomide

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10232041

    Combination of lenalidomide and polypeptide construct, and uses thereof

    Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9636334

    Combination of lenalidomide and polypeptide construct, and uses thereof

    Expires Mon Apr 27 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is lenalidomide?

lenalidomide (LENALIDOMIDE CELGENE EUROPE) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for lenalidomide?

LENALIDOMIDE CELGENE EUROPE is a marketed brand name for lenalidomide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of lenalidomide?

lenalidomide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.